Press Releases

  • Quebec makes new inflammatory bowel disease treatment ENTYVIO® (vedolizumab) available through public drug plan

    2017.05.10

    Gut-selective treatment now funded publicly for Quebecers with ulcerative colitis and Crohn’s disease OAKVILLE, Ontario – May 10, 2017 – Takeda Canada Inc. is pleased to announce that Quebec’s public drug plan has agreed to fund ENTYVIO® (vedolizumab), the first and only gut-selective biologic therapy for inflammatory bowel disease (IBD). ENTYVIO® has been added to the Régie de l'assurance maladie du Québec (RAMQ) Liste des medicaments for adults with moderate or severe ulcerative colitis (UC) regardless of whether they were previously on biologic treatment. For people living with Crohn’s disease (CD), ENTYVIO® is available after failure on all funded anti-TNF therapies or for those...
  • Provincial drug plans, including Ontario and BC, make ENTYVIO® (vedolizumab) available to treat inflammatory bowel disease

    2017.05.09

    Gut-selective treatment now funded publicly for Canadians with ulcerative colitis and Crohn’s disease OAKVILLE, Ontario – May 9, 2017 – Takeda Canada Inc. is pleased to announce that several provinces across Canada including Ontario and British Columbia, have agreed to fund ENTYVIO® (vedolizumab), the first and only gut-selective biologic therapy for inflammatory bowel disease (IBD) through their public provincial drug plans. ENTYVIO® is now funded in Ontario and British Columbia for adults with moderate or severe biologic-naïve and biologic-experienced ulcerative colitis (UC) or Crohn's disease (CD). “We are seeing in clinical practice...
  • TAKEDA CANADA LAUNCHES YOURVANTAGE™ PATIENT SUPPORT PROGRAM FOR MYELOMA PATIENTS PRESCRIBED NINLARO™

    2017.02.03

    Canadians prescribed NINLARO™ will now benefit from personalized support OAKVILLE, Ontario – February 1, 2017 – Takeda Canada Inc. is pleased to support multiple myeloma patients prescribed NINLARO™ (ixazomib) with access to YOURVANTAGE™, a personalized treatment assistance program. In August 2016, Health Canada approved NINLARO™ in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.i NINLARO™ is the first and only oral proteasome inhibitor that provides a needed option for patients managing a devastating, rare, relapsing and incurable...
 

Takeda Pharma